This company listing is no longer active
2142 Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HBM Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.49 |
| 52 Week High | HK$10.50 |
| 52 Week Low | HK$2.40 |
| Beta | 0 |
| 1 Month Change | -21.45% |
| 3 Month Change | -37.28% |
| 1 Year Change | -68.20% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2142 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -12.9% | -3.1% | 1.3% |
| 1Y | -68.2% | -33.9% | 1.6% |
Return vs Industry: 2142 underperformed the Hong Kong Biotechs industry which returned -56.7% over the past year.
Return vs Market: 2142 underperformed the Hong Kong Market which returned -26% over the past year.
Price Volatility
| 2142 volatility | |
|---|---|
| 2142 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in HK Market | 15.7% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2142's share price has been volatile over the past 3 months.
Volatility Over Time: 2142's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 396 | Jingsong Wang | www.harbourbiomed.com |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors.
HBM Holdings Limited Fundamentals Summary
| 2142 fundamental statistics | |
|---|---|
| Market cap | HK$1.83b |
| Earnings (TTM) | -HK$1.17b |
| Revenue (TTM) | HK$233.32m |
7.8x
P/S Ratio-1.6x
P/E RatioIs 2142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2142 income statement (TTM) | |
|---|---|
| Revenue | US$29.73m |
| Cost of Revenue | US$205.00k |
| Gross Profit | US$29.52m |
| Other Expenses | US$178.79m |
| Earnings | -US$149.27m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 99.31% |
| Net Profit Margin | -502.15% |
| Debt/Equity Ratio | 35.9% |
How did 2142 perform over the long term?
See historical performance and comparison